Skip to content
1st Counsel – Lifestyle
Author:
Lir Life Sciences Corp.
LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
June 17, 2026
LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
May 22, 2026
Axis Capital Reports First Quarter Net Income Available to Common Shareholders of $247 Million, or $3.29 Per Diluted Common Share and Operating Income of $257 Million, or $3.42 Per Diluted Common Share
May 8, 2026
LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules
April 28, 2026
LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.
April 20, 2026